

1 (Article)

## 2 Nootropic Effect of Fenugreek Seed Extract against Scopolamine Induced Cognitive

### 3 Decline in Experimental Mice

4 Shalam Mohamed Hussain<sup>1\*</sup>, Nayef Almutairi<sup>2</sup>, Fahad Alrakaf<sup>2</sup>, Mohammed Aljameli<sup>2</sup>,  
5 Muhammad Alshammari<sup>3</sup> and Sulaiman Alnasser<sup>4</sup>

6 <sup>1</sup> Former faculty and independent researcher, College of Pharmacy, Qassim University, Saudi Arabia

7 <sup>2</sup> Graduate students, Unaizah College of Pharmacy, Qassim University, Saudi Arabia

8 <sup>3</sup> Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Saudi Arabia

9 <sup>4</sup> Department of Pharmacology, Unaizah College of Pharmacy, Qassim University, Saudi Arabia

10 \*Correspondence: shalam26@yahoo.co.in

11

12 **Abstract: Background:** Alzheimer's disease affecting about 24 million people world-wide. The socio-economic  
13 burden on world-economies costing more than 172 billion US \$ annually for the US alone. **Objectives:** To  
14 prepare aqueous extract of T. foenum graecum seeds (FSE) to explore the possible treatment for cognitive deficit  
15 in experimental animals. **Materials and methods:** FSE was subjected to preliminary phytochemical evaluation  
16 and antioxidant effect using free radical scavenging method (DPPH). All the animal behavior was video recorded  
17 with no human intervention during observation and animal groupings were blinded to avoid investigator bias.  
18 Different doses of FSE (5%, 10% and 20%), control, standard (Piracetam, 200 mg/kg, IP.) were given for male  
19 albino mice a period of 15 days followed by cognitive assessment in elevated plus maze and novel objection  
20 recognition tests. Transfer latencies and time exploring novel and familiar objects were recorded in respective  
21 tests. Retention of this learned-task was examined again 24 h later and inflexion ratio (IR) and discriminative  
22 index (DI) were calculated respectively. Next in the second set of experiment same groups and treatments were  
23 continued but scopolamine was administered to all the groups except normal control one hour after the last dose  
24 and examined similarly. **Results:** FSE showed potential antioxidant effect and a dose dependent increase in  
25 transfer latency and improved DI indicating a nootropic effect. FSE at 20% showed significant reversal of  
26 scopolamine induced dementia in the second set of experiment. **Conclusion:** FSE improved memory as well as  
27 reversed the chemically induced memory deficits in experimental mice.

28 **Keywords:** Fenugreek, Alzheimer's disease, nootropic, cognitive disorders, herbs, memory

29

30

31

## 32 1. Introduction

33 Alzheimer's disease (AD) is a neurodegenerative disorder that it is the most common cause of  
34 dementia in the old age who are slowly deprived in memory and the ability to carry out the simple  
35 tasks. People with AD tend to lose their cognitive skills, including behavioral disabilities and loss of  
36 functional autonomy. Both genetic and environmental factors are known to be an AD risk factor. Free  
37 radicals, elevated oxidative stress and mitochondrial dysfunction, eventually triggering neuronal /  
38 synaptic and neurodegenerative dysfunction<sup>1</sup>. According to the National Institute of Health, some 18  
39 million people worldwide have been affected and are estimated to rise by 33 to around 65.7 million  
40 by 2030 and 115.4 million by 34 by 2050<sup>2</sup>. The Alzheimer's Disease Association estimated that  
41 Alzheimer's disease accounts for 50 to 80 per cent of cases of dementia worldwide, with the largest  
42 identified risk factor rising the age of 65 and older and the prevalence rate of Alzheimer's disease was  
43 not documented yet<sup>1, 3</sup>. Several drugs, such as rivastigmine and donepezil, are used to treat this  
44 condition as inhibitors of Acetyl-cholinesterase (AChE) licensed by a variety of global food and drug  
45 companies.<sup>4</sup> Despite the use of these inhibitors to control the role of AChE, there is a growing need  
46 to seek new medications. Therefore, several studies for this reason were aimed at new natural  
47 compounds with potential antioxidant properties and with very low side effects have been reported.  
48 As a consequence, the use of imitative herbal medicines for AD treatment is on the increase. As is  
49 already known, acetylcholine is the key neurotransmitter that plays a vital role in AD. For this reason,  
50 several trials have been performed to use AChE suppressors.<sup>5, 6, 7</sup>

51 Fenugreek is one of the most important plants with antioxidant properties. Its seeds and leaves  
52 are used for food and also in traditional medicines. Some studies stated that trigonelline, a compound  
53 isolated from fenugreek, exhibited nerve regeneration and enhanced memory activity in AD-induced  
54 mice. Its seeds and leaves are used in food and herbal medicine as well. Fenugreek seeds have been  
55 found to have a variety of compounds, such as steroidal. The seeds of which are rich in choline,  
56 alkaloid, flavonoid, polyphenol antioxidants and other hydroxy-aromatic components which help it  
57 in exhibiting anti-oxidant, anti-inflammatory and neuro-protective properties. Therefore, the  
58 purported efficacy of this herb in enhancing cognition was explored in the current study.<sup>8-12</sup>(Figure  
59 1)

## 60 2. Materials and Methods

### 61 2.1 Drugs and chemicals

62 Piracetam (Nootropil injection, a commercial product), standard nootropic agent. Commercially  
63 available scopolamine hydrobromide was purchased from a local pharmacy. Acetylthiocholine  
64 iodide, 5, 5'-dithiobis-2-nitrobenzoic acid, DPPH (2, 2, diphenyl-1-picryl hydrazil radical) was  
65 procured from Fluka Chemie (Buchs, Switzerland). All the other chemical agents used were of  
66 analytical grade available in our chemistry lab.

### 67 2.2 Animals

68 Male Swiss albino mice were procured from the commercial supplier and breeder in Riyadh,  
69 Saudi Arabia. Animal studies were performed after obtaining necessary permission from  
70 Institutional Animal Ethics Committee (IAEC UCP/18-19/01). After procuring the mice, they were  
71 acclimatized for 7 days and housed in groups of six under standard laboratory condition with  
72 relative humidity of 45-55% and light/ dark cycle of 12 hours. They were fed with synthetic  
73 standard pellet diet available locally and were supplied water *ad libitum*. Male mice weighing  
74 between 25-35 gm were used in this study and were fasted for 3 hrs prior to any administration  
75 of vehicle/standard/extract. All the experimental procedures were carried out as per the  
76 protocol in a dimly lit room during the light period (8:00 to 16:00 hour).

### 77 2.3 Experimental design

### 78 2.3.1 Preparation of fenugreek seed extract

79 The fresh *Fenugreek seeds* were purchased locally. The seeds were washed with tap water and  
80 dried in the shade at room temperature for 2 days. Then the dried seeds were kept for  
81 germination for 1 day in a covered muslin cloth. The germinated seeds were dried and  
82 powdered and sieved. Different concentrations (5%, 10% and 20% w/v) were prepared in water  
83 and stirred for two hours in magnetic stirrer and then centrifuged for 1 hour at 5000rpm.  
84 Supernatant was collected for administration.

### 85 2.3.2 Determination of antioxidant activity of FSE

86 Method followed as per the available references and consists of taking 3 ml of 0.05 mM DPPH in  
87 methanol with 30  $\mu$ L of the different concentrations of the extract in phosphate buffer (pH 7.4),  
88 mixed well and kept in dark for 20 min followed by reading absorbance. Blank reading was  
89 taken for DPPH alone without any extract. IC50 values for the different extracts were calculated  
90 and percentage inhibition was calculated as,

91 % inhibition =  $[(Ab - As) / Ab] * 100$ , where Ab is control absorbance, As- sample absorbance.  
92 Vitamin C 1mM and 1mM vitamin E were used as positive control<sup>13,14</sup>.

### 93 2.3.3 Acute toxicity test

94 Acute toxicity test of fenugreek seed extract was carried as per the method described in  
95 [OECD Test Guidelines 425 \(Up and Down Procedure\)](#)<sup>15</sup> wherein a single albino mouse was  
96 given 2000 mg/kg p.o. as single dose and observed for first 30 min, then for 4 h. After survival  
97 of treated mouse, 4 additional mice were administered with the same dose under same  
98 conditions. Observed for 2 days for any signs of toxicity or death.

### 99 2.3.4 Assessment of cognitive performance

100 For all experimental procedures, all groups of treatments were blinded to the investigators to  
101 avoid any bias. The apparatus used for testing were cleaned with 5% alcohol before using each  
102 mouse to remove any animal cues. All the experiments were conducted in dim light and were  
103 video recorded for offline analysis

#### 104 2.3.4.1 Animal groupings

105 Mice were divided into following groups each containing six, group I: Control (Distilled water  
106 10ml/kg, p.o.), group II: Standard (Piracetam, 200 mg/kg, IP.), group III: Low dose of FSE (5%), po  
107 Group IV: Medium dose of FSE (10%, po), Group V: High dose of FSE (20%, p.o). They were  
108 fasted for 3 h prior to the administration but water was supplied *ad libitum*. All the groups of  
109 mice were administered respective treatment as shown in the protocol (Figure 2).

#### 110 2.3.4.2 Elevated plus-maze

111 The Elevated Plus maze (EPM) used was fabricated locally with wood and dimensions meeting  
112 the published literature. It had two open arms and two closed arms, crisscrossing each other  
113 forming a plus. The closed arms and open arms were 25 cm  $\times$  10 cm  $\times$  20 cm and 25 cm  $\times$  10 cm  
114 respectively with a central platform of 10 X 10 cm area. The entire maze was elevated to a  
115 height of 90 cm with a wooden column. All procedures were conducted in a dimly lit dark  
116 room<sup>16-18</sup>. All the parameters were recorded using a web cam fixed above EPM to the roof and  
117 connected to a computer for recording and offline analysis. On day 15, 1 h after the dose, each  
118 mouse was placed at the end of an open arm, facing away from the central platform. Transfer  
119 latency (TL) i.e. the time taken by mouse with all its four legs to move into one of the enclosed

120 arms was recorded as the initial transfer latency (L1) on the first day. If the animal does not  
121 enter into one of the enclosed arms within 90 s, it was gently pushed into one of the two  
122 enclosed arms and the TL was assigned as 90 s. The mouse was allowed to explore the maze for  
123 next 10 s and then returned to its home cage. Retention of this learned-task was examined again  
124 24 h later (L2). The whole apparatus was thoroughly cleaned with 5% alcohol before placing each  
125 animal in the maze to avoid animal cues. The inflexion ratio (IR) was calculated by the following  
126 formula,  $(IR) = (L2 - L1) / L1$ , Where  $L1$  is the initial TL (s) on 1st day and  $L2$  is the TL (s) on the  
127 2nd day.

#### 128 2.3.4.3 Novel object recognition task<sup>19-21</sup>

129 The apparatus was made up of wood of a rectangular box measuring 50 cm × 50 cm × 50 cm. It  
130 was placed in dimly lit dark room. All the parameters were recorded using a video camera. Mice  
131 were divided into following groups each containing six. They were fasted for 3 hrs prior to the  
132 administration but water was supplied *ad libitum*. On day 17, 1 h after the dose, each mouse was  
133 tested in a 30 cm X 30 cm rectangular box. The test consists of 3 phases, 1. habituation session 2.  
134 training session 3. test session. All animals were given one habituation session in which they  
135 were allowed to explore the apparatus (without objects) for 10 min. For the training session, each  
136 mouse was placed into the box with two identical objects (1 and 2) and allowed to explore for 5  
137 min (training). The time spent by the animal exploring each object and also the time spent by the  
138 animal exploring both objects and the box were measured. 24 h after the training, one of the  
139 objects was replaced with a novel object (object number 3, novel) and the other object is same as  
140 used for training (1, familiar object). Each mouse was individually tested and video graphed for  
141 5 minutes. Time spent by mouse exploring objects determined.

#### 142 2.3.4.4 Scopolamine induced amnesia in mice using above tests

143 In the second set of experiment same groups and treatment period were maintained but  
144 scopolamine (1 mg/kg, IP) was administered to all the groups one hour after last dose on day 19  
145 in the respective tests (EPM and NORT) and then examined to record as above. Retention of this  
146 learned-task was examined again 24 h later and parameters were calculated as per the procedure  
147 in above respective methods.

#### 148 2.4 Statistical Analysis

149 All the results were expressed as mean ± standard error. The data were analyzed using ANOVA  
150 followed by tukey's multiple comparison post hoc test.  $p < 0.05$  were considered as significant.  
151 The statistical analysis was done using the SPSS software package for Windows, version 20,  
152 Chicago, USA.

153

### 154 3. Results

#### 155 3.1 Antioxidant activity of FSE

156 The decrease in DPPH absorption in the presence of varying concentrations of extract was monitored and it  
157 was noticed that the extract showed a dose dependent decrease in the absorbance of DPPH radical. IC<sub>50</sub> value  
158 for the extract was found to be 9.93 µg/ml. These results indicated an antioxidant potential of seed. (Table 1)

#### 159 3.2 Effect of FSE on transfer latency (TL) in elevated plus maze

160 Effect of FSE on TL in mice were recorded with elevated plus maze apparatus where piracetam 200 mg/kg and  
161 FSE with three different dose levels (w/v) i.e. 5%, 10% and 20%, treated groups have shown a decrease in

162 transfer latencies leading to corresponding increase in inflexion ratios as compared to normal control. But  
163 statistically significant effect ( $P < 0.05$ ) was observed with high dose 20 % of FSE and piracetam ( $P < 0.05$ ).  
164 (Figure 3)

### 165 3.3 Effect of FSE on transfer latency in scopolamine induced amnesic mice in EPM

166 The effect of the vehicle, scopolamine (1 mg/kg), FSE (5%, 10% and 20%) and piracetam (200 mg/kg) are  
167 shown in Figure 4. The scopolamine alone treated group showed a significant ( $P < 0.01$ ) increase in TL values  
168 on the acquisition as well as on the retention days (decrease in inflexion ratio) as compared to vehicle control  
169 mice, indicating an impairment in learning and memory. Whereas in the acquisition as well as retention trial  
170 FSE demonstrated dose dependent decrease in the TL (increase in inflexion ratio) when compared to the  
171 scopolamine alone treated group ( $P < 0.01$ ). Piracetam (200 mg/kg IP.) exhibited marked decrease ( $P < 0.01$ )  
172 in TL in comparison with the scopolamine. However, FSE at the dose levels 20% and 10% showed a  
173 comparable decrease in the TL ( $P < 0.05$ ).

### 174 3.4 Effect of FSE for object exploration in mice using novel object recognition test

175 Effect of FSE on inflexion ratios in mice were recorded with elevated plus maze apparatus. Piracetam 200  
176 mg/kg and FSE with three different dose levels i.e. 100, 200 and 400 mg/kg, treated groups have shown  
177 decrease in transfer latencies leading to increase in inflexion ratios when compared to control. But statistically  
178 significant effect ( $P < 0.05$ ) was observed with high doses i.e. 10 and 20% of FSE groups only indicating a  
179 dose dependent nootropic like effect. Piracetam also has increased the inflexion ratio very significantly ( $P <$   
180 0.01). (Figure 5)

### 181 3.5 Effect of FSE on time spent exploring in scopolamine induced dementia in mice using NORT

182 The effect of the vehicle, scopolamine (1 mg/kg, po), FSE (5%, 10% and 20%) and piracetam (200 mg/kg)  
183 were evaluated at the end of treatment period. The scopolamine (1 mg/kg) control group showed a significant  
184 ( $P < 0.01$ ) increase in exploration time for novel object on the acquisition as well as on the retention days  
185 (decrease in discrimination index) as compared to vehicle control mice, indicating an impairment in learning  
186 and memory. In the acquisition as well as retention trial, FSE demonstrated dose dependent decrease in the  
187 exploration time (increase in DI) as compared to the scopolamine control group. Piracetam (200 mg/kg IP.)  
188 exhibited marked decrease ( $P < 0.01$ ) in exploration time in comparison with the scopolamine control group.  
189 (Figure 6)

## 190 4. Discussion

191 Alzheimer's disease is a neurogenerative condition associated with a decrease in cognitive  
192 ability.<sup>4</sup> Given the seriousness and high prevalence of this disease, the allopathic medical system  
193 has failed to provide a suitable cure.<sup>22</sup> The present study therefore concentrated on investigating  
194 the memory enhancing function of the FSE in a chemical-induced amnesia models. In this study  
195 the exteroceptive model was used for evaluating the nootropic activity (memory enhancing) of  
196 FSE on learning and memory processes, which was indicated by decreased transfer latency and  
197 increased inflexion ratio in EPM. The interoceptive models used were amnesia induced by  
198 scopolamine, which was indicated by prevention of fall in transfer latency and inflexion ratio in  
199 EPM<sup>16-18</sup>. The present study suggests that FSE possesses memory enhancing activity in view of its  
200 decreased transfer latency and increased inflexion ratio in EPM. This suggests that the FSE has  
201 pronounced nootropic effect which was comparable to nootropil (standard) in the study. FSE  
202 also exhibited a facilitatory effect on the retention of memory in scopolamine induced amnesic  
203 mice.

204 Similarly, in another group of models used by NORT, scopolamine substantially increased the e  
205 xploration period suggesting that scopolamine induced cognitive impairment in this model. Pret  
206 reatment with different doses of FSE greatly increased the ability of the treated mice to identify

207 novel artifacts. Administration of different doses of FSE led to enhancement in indices of  
208 memory in normal as well as scopolamine induced memory impaired mice in EPM as well as  
209 NORT tests in the present. It is well known that cholinergic neuronal systems play an  
210 important role in cognitive deficiencies associated with AD, aging and neurodegenerative  
211 diseases.<sup>23,24</sup> In our study, amnesia caused by scopolamine is evident from the results obtained  
212 and its reversal with the prior treatment of FSE indicating the activation of cholinergic system by  
213 FSE. Also, the ability of the FSE to scavenge the oxidative free radical and to prevent induced  
214 tissue damage by its potential antioxidant activity in the DPPH free radical scavenging assay  
215 contributes to its cognition enhancing effect. In addition, FSE has phenolic and flavonoid  
216 compounds which are proven antioxidants. There are also numerous studies on the antioxidant  
217 capacity of fenugreek seeds.<sup>25-27</sup> These findings indicate that they have antioxidant ability to  
218 prevent chemically mediated memory deficits. As a consequence, it can be concluded from these  
219 findings that FSE may provide a potential advantage in the amelioration of Alzheimer's disease  
220 type memory loss due to its probable potential for activation of the cholinergic system and/or  
221 free radical scavenging capability that can provide neuroprotection in the prevention or  
222 management of this disease. The effects observed with FSE are in agreement with the previous  
223 published studies wherein fenugreek extract as well as its primary constituent, trigonellin  
224 exhibited potential cognitive effect in various chemically induced cognitive deficit models such  
225 as.<sup>24,26-30</sup>

226 Although this research was not an exhaustive adventure to draw any conclusions, it is proof of  
227 our hypothesis. However, more studies are required to further investigate the potential effects of  
228 FSE on AChE in various parts of the brain, amyloid beta plaques, the role of other  
229 neurotransmitters such as glutamate, gamma aminobutyric acid (GABA) and catecholamines.

## 230 5. Conclusions

231 In this study, we concentrated on exploring FSE's ability to improve memory in laboratory mice as  
232 well as reversing chemically induced memory deficits in experimental mice. The results of the invitro  
233 studies have shown that FSE is an antioxidant and the results of the in vivo analysis have concluded  
234 that FSE has nootropic function in the absence of cognitive deficits and has also been effective in  
235 preventing chemically induced memory deficits in experimental mice. The mechanism by which FSE  
236 has shown these properties can be related to its antioxidant, neuroprotective properties, its choline  
237 content or activation of acetylcholine system in brain. In the light of above, it may be worthwhile to  
238 explore the potential of these seeds in the management of AD patients

### 239 Author Contributions:

240 "Conceptualization, SMH.; methodology, SMH.; software, MS and SN.; validation, NA, FA and MA.; formal  
241 analysis, SMH.; investigation, NA, FA and MA.; resources, MS and SN.; data curation, SMH.; writing—SMH.;  
242 writing—review and editing, SMH, MS and SN; supervision, SMH.; project administration, NA, FA and MA.  
243 All authors have read and agreed to the published version of the manuscript.

244 **Funding:** Please add: "This research received no external funding.

### 245 Acknowledgments:

246 Authors would like to thank administrative and technical support provide by thee college authorities

247 **Conflicts of Interest:** The authors declare no conflict of interest.

## 248 References

- 249 1. Alzheimer's Disease and Related Dementias | National Institute on Aging.  
250 <https://www.nia.nih.gov/health/alzheimers>. Accessed September 23, 2020.
- 251 2. Alzheimer's Disease Fact Sheet | National Institute on Aging. [https://www.nia.nih.gov/health/alzheimers-](https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet)  
252 [disease-fact-sheet](https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet). Accessed September 23, 2020.

- 253 3. International D. *World Alzheimer Report 2019: Attitudes to Dementia; World Alzheimer Report 2019: Attitudes to*  
254 *Dementia*.
- 255 4. P.A. D, R.S. M, M. G, J.D. L, J. F. Alzheimer's disease clinical and research update for health care  
256 practitioners. *J Aging Res*. 2013;2013(Mci).
- 257 5. Kennedy D, Scholey A. The Psychopharmacology of European Herbs with Cognition-Enhancing  
258 Properties. *Curr Pharm Des*. 2006;12(35):4613-4623. doi:10.2174/138161206779010387
- 259 6. Kiefer D. An herbal mixture for enhanced memory. *Integr Med Alert*. 2019;22(3).
- 260 7. Fu LM, Li JT. A systematic review of single Chinese herbs for Alzheimer's disease treatment. *Evidence-based*  
261 *Complement Altern Med*. 2011;2011. doi:10.1093/ecam/nep136
- 262 8. Yadav UCS, Baquer NZ. Pharmacological effects of *Trigonella foenum-graecum* L. in health and disease.  
263 *Pharm Biol*. 2014;52(2):243-254. doi:10.3109/13880209.2013.826247
- 264 9. Zhou J, Chan L, Zhou S. *Trigonelline: A Plant Alkaloid with Therapeutic Potential for Diabetes and Central*  
265 *Nervous System Disease*. Vol 19.; 2012.
- 266 10. Al-Asadi JN. *OPEN ACCESS Therapeutic Uses of Fenugreek (Trigonella Foenum-Graecum L.) OPEN ACCESS*.
- 267 11. Zandi P, Basu SK, Khatibani LB, et al. Fenugreek (*Trigonella foenum-graecum* L.) seed: a review of  
268 physiological and biochemical properties and their genetic improvement. *Acta Physiol Plant*. 2015;37(1):1-14.  
269 doi:10.1007/s11738-014-1714-6
- 270 12. Panda S, Biswas S, Kar A. Trigonelline isolated from fenugreek seed protects against isoproterenol-induced  
271 myocardial injury through down-regulation of Hsp27 and  $\alpha$ B-crystallin. *Nutrition*. 2013;29(11-12):1395-1403.  
272 doi:10.1016/j.nut.2013.05.006
- 273 13. Ho KY, Tsai CC, Chen CP, Huang JS, Lin CC. Screening of Brazilian plant extracts for antioxidant activity  
274 by the use of DPPH free radical method. *Phyther Res*. 2001;15(2):127-130. doi:10.1002/ptr.687
- 275 14. Sharma OP, Bhat TK. DPPH antioxidant assay revisited. *Food Chem*. 2009;113(4):1202-1205.  
276 doi:10.1016/j.foodchem.2008.08.008
- 277 15. OECD. OECD Guidelines for the Testing of Chemicals, Section 4, Test No. 425: Acute Oral Toxicity - Up-  
278 and-Down Procedure. *Guidel Test Chem*. 2001;(December):26. doi:10.1787/9789264071049-en
- 279 16. Elevated Plus Maze for Mice | Protocol. <https://www.jove.com/t/1088/elevated-plus-maze-for-mice>.  
280 Accessed September 24, 2020.
- 281 17. Komada M, Takao K, Miyakawa T. Elevated plus maze for mice. *J Vis Exp*. 2008;(22):1088. doi:10.3791/1088
- 282 18. Dhingra D, Kumar V. Memory-enhancing activity of palmatine in mice using elevated plus maze and  
283 Morris water maze. *Adv Pharmacol Sci*. 2012;2012. doi:10.1155/2012/357368
- 284 19. Scopolamine-induced deficits in a two-trial object recogniti...: NeuroReport.  
285 [https://journals.lww.com/neuroreport/Abstract/1997/03240/Scopolamine\\_induced\\_deficits\\_in\\_a\\_two\\_trial\\_obje](https://journals.lww.com/neuroreport/Abstract/1997/03240/Scopolamine_induced_deficits_in_a_two_trial_obje)  
286 [ct.23.aspx](https://journals.lww.com/neuroreport/Abstract/1997/03240/Scopolamine_induced_deficits_in_a_two_trial_obje). Accessed September 24, 2020.
- 287 20. Lueptow LM. Novel object recognition test for the investigation of learning and memory in mice. *J Vis Exp*.  
288 2017;2017(126):e55718. doi:10.3791/55718

- 289 21. Botton PH, Costa MS, Ardais AP, et al. Caffeine prevents disruption of memory consolidation in the  
290 inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. *Behav Brain Res.*  
291 2010;214(2):254-259. doi:10.1016/j.bbr.2010.05.034
- 292 22. Schneider L, DeKosky S, Farlow M, Tariot P, Hoerr R, Kieser M. A Randomized, Double-Blind, Placebo-  
293 Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type. *Curr Alzheimer Res.*  
294 2005;2(5):541-551. doi:10.2174/156720505774932287
- 295 23. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: Complementary  
296 mechanisms in the treatment of Alzheimer's disease. *Neurotox Res.* 2013;24(3):358-369. doi:10.1007/s12640-013-  
297 9398-z
- 298 24. Anjaneyulu K, Rai KS, Rajesh T, Nagamma T, Bhat KMR. Therapeutic efficacy of fenugreek extract or/and  
299 Choline with docosahexaenoic acid in attenuating learning and memory deficits in ovariectomized rats. *J Krishna*  
300 *Inst Med Sci Univ.* 2018;7(2):10-20.
- 301 25. Bafadam S, Beheshti F, Khodabakhshi T, et al. Trigonella foenum-graceum seed (Fenugreek)  
302 hydroalcoholic extract improved the oxidative stress status in a rat model of diabetes-induced memory  
303 impairment. *Horm Mol Biol Clin Investig.* 2019;39(2):1-13. doi:10.1515/hmbci-2018-0074
- 304 26. Moin M, Kassae SM. Effect of Fenugreek on Memory and Learning and also Antioxidant Capacity in  
305 Hippocampus of Type II Diabetic Rats. *J Ilam Univ Med Sci.* 2017;25(4):13-23. doi:10.29252/sjimu.25.4.13
- 306 27. Khalili M, Alavi M, Esmail-Jamaat E, Baluchnejadmojarad T, Roghani M. Trigonelline mitigates  
307 lipopolysaccharide-induced learning and memory impairment in the rat due to its anti-oxidative and anti-  
308 inflammatory effect. *Int Immunopharmacol.* 2018;61(September 2017):355-362. doi:10.1016/j.intimp.2018.06.019
- 309 28. Chowdhury AA, Gawali NB, Munshi R, Juvekar AR. Trigonelline insulates against oxidative stress,  
310 proinflammatory cytokines and restores BDNF levels in lipopolysaccharide induced cognitive impairment in  
311 adult mice. *Metab Brain Dis.* 2018;33(3):681-691. doi:10.1007/s11011-017-0147-5
- 312 29. Fahanik-Babaei J, Baluchnejadmojarad T, Nikbakht F, Roghani M. Trigonelline protects hippocampus  
313 against intracerebral A $\beta$ (1-40) as a model of Alzheimer's disease in the rat: insights into underlying mechanisms.  
314 *Metab Brain Dis.* 2019;34(1):191-201. doi:10.1007/s11011-018-0338-8
- 315 30. Prema A, Thenmozhi AJ, Manivasagam T, Essa MM, Akbar M, Akbar MD. Fenugreek seed powder  
316 nullified aluminium chloride induced memory loss, biochemical changes, A $\beta$  burden and apoptosis via  
317 regulating Akt/GSK3 $\beta$  signaling pathway. *PLoS One.* 2016;11(11):1-19. doi:10.1371/journal.pone.0165955

318

319



320 1. Table


321 2. Table 1. Antioxidant activity of FSE using DPPH free radical scavenging activity

3. S.No	4. Concentration of extract (µg/ml of FSE)	5. Inhibitory activity (%)	6. IC50 µg/ml
7. 1	8. 10	9. 50	10. 9.93
11. 2	12. 20	13. 83	
14. 3	15. 30	16. 85	
17. 4	18. 40	19. 86	
20. 5	21. 50	22. 86	
23. 6	24. 60	25. 87	
26. 7	27. 70	28. 89	
29. 8	30. 80	31. 90	
32. 9	33. 90	34. 90	
35. 10	36. 100	37. 90	

322 38.

323

324 40. Figures



325 41.


326 42.

327

328 44. Figure 2: Detailed protocol for the experimental design for normal and scopolamine induced cognitive  
329 deficit in mice

330 45.

331 46.



332 47. Fig 3: Effect of FSE on inflexion ratio in mice in elevated plus maze

333 48.

334 49.

335 50.

336 51.

337 52.

338 53.

339 54.

340 55.


341 56.

342 57.

343 58.


344 59.

345



347 61. Figure 4: Effect of FSE on inflexion ratio in scopolamine induced amnesic mice in elevated plus maze

348 62.




357 71. Statistical analysis by one-way ANOVA followed by Dunnett's't' test. Values are expressed as  
 358 mean  $\pm$  S.E.M ( $n = 6$ ). \* $p < 0.05$ , \*\* $p < 0.01$  compared with normal control group. ## $p < 0.01$  when compared  
 359 with disease control (Scopolamine)

360 72.

361 73. Figure 5: Effect of FSE on discrimination index in mice in novel object recognition test

362



372 84. Statistical analysis by one-way ANOVA followed by Dunnett's' test. Values are expressed as mean  $\pm$  S.E.M  
 373 ( $n = 6$ ). \* $p < 0.05$ , \*\* $p < 0.01$  compared with normal control group

374


375

376

377

378 85. Figure 6: Effect of FSE on discrimination index in scopolamine treated mice in novel object recognition  
379 test

380 86.



381

382

383

384

385

386

387 89. Statistical analysis by one-way ANOVA followed by Dunnett's test. Values are expressed as mean ± S.E.M  
388 ( $n = 6$ ). \* $p < 0.05$ , \*\* $p < 0.01$  compared with scopolamine control group. ## $p < 0.01$  when compared with normal  
389 control